News archive
Email Alerts
Sign up to receive the latest news from Evocutis by email
Contact Us
Get in touch with our specialist team of scientists.
Our Services
We offer a highly specialised and flexible portfolio of assays, models and clinical protocols.2012
Highlights from the year ended 31 July 2012
Announcement of Strategic Review
03 December 2012
Evaluation of a number of strategic options planned to maximise value for shareholders
Date Set for Announcement of Preliminary Results
23 November 2012
TR-1 Shareholder Notification of Major Interest in Shares
21 September 2012
Confirmation of change of shareholding in Evocutis plc
Launch of LabSkin™ as a Consumable Research Tool
11 September 2012
Research grade living skin equivalent model, LabSkin™, now available for purchase.
Issue of Equity and Grant of Share Options
01 August 2012
Evocutis announces the issue of 595,238 new ordinary shares.
Increased revenues compared to the last financial year and developments to introduce LabSkinTM as a commercially available product.
Interim CEO Appointed
30 April 2012
Evocutis welcomes Senior Non-Executive Director, Dr Gwyn Humphreys, as interim CEO.
Dr Stephen Jones steps down as CEO
04 April 2012
Dr Jones is to stay at Evocutis until a new CEO is appointed.
Interim Results for Evocutis plc 2012
22 March 2012
Significant revenue increase in the first half-year reflects the progress being made in commercialising new and existing technology platforms.
We have been accepted as a member of the In Vitro Testing Industrial Platform (IVTIP) and look forward to supporting its work in promoting alternatives to animal testing.
Launch of Standard Panel of P. acnes for Anti-acne and Blemish Reduction Product Claims
14 March 2012
We now have a highly defined panel of 36 strains of Propionibacterium acnes to improve the reliability of testing for developers of anti-acne and blemish-reduction products.
Evocutis validates anti-ageing LabSkin™ model
27 January 2012
The value of LabSkin(TM) as a marketing tool has been enhanced through its validation for use in supporting anti-ageing product claims.
New facilities integrate with LabSkin(TM) models for animal-free testing of ingredients and products on skin structure
2011
Director's Dealing
23 December 2011
The Company's Chairman, Tom Bannatyne, acquires further shares in Evocutis plc
Cosmetics Design Interview Evocutis at Microbiota
21 December 2011
Hear how our skin equivalent model, LabSkin, could eventually replace the need for clinical testing in Cosmetics Design's video-cast.
Notice of AGM and Report & Accounts
15 December 2011
Publication of annual report & accounts for year ending July 2011 and notice of AGM
Highlights from the financial year ended 31 July 2011
New LabSkin™ model to validate antimicrobial claims made on cosmetic
ingredients and formulations.
Ticker change: Syntopix (SYN) changes to Evocutis (EVO)
25 October 2011
Evocutis plc is now trading under the ticker AIM:EVO.
The directors of the Company are pleased to announce that shareholders approved the resolution earlier today.
Syntopix Group Business Update
30 September 2011
Syntopix Group is pleased to provide a business update for the period ended 31 July 2011.
Syntopix Business Update
15 September 2011
Syntopix provides an update on three opportunities: SYN1113 (for the treatment of acne) and ongoing programmes with Sinclair Pharma and Beiersdorf AG.
Syntopix Announce Change of Registered Office
08 July 2011
Syntopix are pleased to announce a change of registered office.
Syntopix Directorate Change
21 June 2011
Dr. Jonathan Cove will resign as a director of the Company, effective from 1 July 2011.
Result of 2011 Syntopix General Meeting
23 May 2011
Syntopix is pleased to announce that all resolutions were duly passed by Shareholders at the General Meeting held earlier today.
Syntopix announce subdivision of current issued share capital and notice of General Meeting
Syntopix Business Update
27 April 2011
An update on three opportunities: SYN1113 (for the treatment of acne) and ongoing programmes with Sinclair Pharma and Beiersdorf AG
Syntopix to research biofilms for Beiersdorf AG
17 January 2011
Syntopix has signed a research agreement with Beiersdorf AG ("Beiersdorf"), an international branded consumer goods company with a focus on skin care.
Syntopix Annual Report and notice of AGM
14 January 2011
The Annual Report and Accounts for the year ended 31 July 2010, the Notice of the Annual General Meeting and the Form of Proxy were posted to shareholders on 14 December 2010
2010
Grant of share options to Directors
03 December 2010
On 2 December 2010, a total of 123,790 options over the Company's ordinary shares were granted to Directors pursuant to the Syntopix Executive Share Option Scheme.
Syntopix Final Results
29 November 2010
Syntopix audited final results for the year ended 31 July 2010.
Appointment of Broker
11 November 2010
Syntopix has appointed XCAP Securities Plc as the Company's Broker with immediate effect.
Second Agreement with Sinclair Pharma
01 November 2010
Syntopix has signed a second agreement with Sinclair Pharma plc (LON:SPH) ("Sinclair"), the international speciality pharmaceutical company.
Agreement with Global Consumer Products Company
23 August 2010
Syntopix announces it has signed an exclusive agreement with a company that is a world leader in marketing home, health and personal care brands
Syntopix Directorate Change
22 June 2010
Syntopix has announced that Alan Aubrey will step down as a non-executive director with immediate effect.
Agreement with Sinclair Pharma plc
22 April 2010
Syntopix has signed an agreement with Sinclair Pharma plc, the international specialty pharma company, to work together on the identification of an antimicrobial compound to synergise and augment the activity of a key product for Sinclair
Result of Syntopix General Meeting
31 March 2010
At the Company's General Meeting held today, all the resolutions were duly passed
Syntopix Interim Results
12 March 2010
Syntopix interim results for the six months ended 31 January 2010
Result of AGM 2010
20 January 2010
Syntopix Group plc announces that all resolutions proposed at the Company's Annual General Meeting held today were duly passed.